المؤلفون: Samuel, Preethi S.^1,2 preethisusan107@gmail.com, Olaleye, Folake^1,3, Longo, Maria^1,4, Berkowitz, Leonard⁵

المصدر: Journal of Pharmacy Practice. Dec2024, Vol. 37 Issue 6, p1400-1404. 5p.

مصطلحات موضوعية: *DARUNAVIR, *RILPIVIRINE, *COMBINATION drug therapy, *NON-nucleoside reverse transcriptase inhibitors, *VIRAL load, *HIV infections, *MULTIDRUG resistance, *DESCRIPTIVE statistics, *RNA, *DRUG efficacy, *ANTI-HIV agents, *CASE studies, *PATIENT satisfaction, *DATA analysis software, *THIAZOLES

المؤلفون: Christopoulos, Katerina, Smith, Mollie, Pareek, Priyasha, Dawdani, Alicia, Erguera, Xavier, Dance, Kaylin, Walker, Ryan, Grochowski, Janet, Mayorga-Munoz, Francis, Hickey, Matthew, Johnson, Mallory, Sauceda, John, Gutierrez, Jose, Montgomery, Elizabeth, Colasanti, Jonathan, Collins, Lauren, McNulty, Moira, Koester, Kimberly

المصدر: Journal of the International AIDS Society. 27(11)

مصطلحات موضوعية: adherence, antiretroviral agents, cabotegravir, injections, rilpivirine drug combination, viral suppression, Humans, Female, Adult, Male, HIV Infections, Middle Aged, Pyridones, Anti-HIV Agents, Rilpivirine, Qualitative Research, Interviews as Topic, United States, Medication Adherence, Chicago, San Francisco, Diketopiperazines

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/4pc5k0f5
https://escholarship.org/content/qt4pc5k0f5/qt4pc5k0f5.pdf

المؤلفون: Kilcrease, Christin¹ Cmk.career@gmail.com, Agwu, Allison², Weld, Ethel D³

المصدر: American Journal of Health-System Pharmacy. 11/15/2024, Vol. 81 Issue 22, p1136-1141. 6p.

مصطلحات موضوعية: *DIAGNOSIS of HIV infections, *RILPIVIRINE, *PATIENT compliance, *HIV, *ANTIRETROVIRAL agents, *HIV-positive persons, *HIV infections, *TREATMENT effectiveness, *ANTIVIRAL agents, *HIGHLY active antiretroviral therapy, *VIREMIA, *ANTI-HIV agents, *DRUGS, *SUBCUTANEOUS injections

المؤلفون: Damas, José¹ jose.damas-fernandez@chuv.ch, Munting, Aline¹, Fellay, Jacques^2,3, Haerry, David⁴, Marzolini, Catia^5,6, Tarr, Philip E⁷, Steffen, Ana⁸, Braun, Dominique L⁹, Stoeckle, Marcel⁵, Bernasconi, Enos¹⁰, Tshikung, Olivier Nawej¹¹, Fux, Christoph A¹², Darling, Katharine E A¹, Béguelin, Charles¹³, Wandeler, Gilles¹³, Cavassini, Matthias¹, Surial, Bernard¹³ jose.damas-fernandez@chuv.ch, (SHCS), the Swiss HIV Cohort Study

المصدر: Clinical Infectious Diseases. 10/15/2024, Vol. 79 Issue 4, p990-998. 9p.

مصطلحات موضوعية: *LAMIVUDINE, *RILPIVIRINE, *ANTIRETROVIRAL agents, *AFRICAN Americans, *RESEARCH funding, *BODY weight, *DRUG therapy, *TENOFOVIR, *HIV-positive persons, *LIPIDS, *HIV infections, *DESCRIPTIVE statistics, *LONGITUDINAL method, *CHOLESTEROL, *WAIST-hip ratio, *ANTHROPOMETRY, *CONFIDENCE intervals, *TRIGLYCERIDES, *TIME

مصطلحات جغرافية: SWITZERLAND

المؤلفون: Ring, Kyle^1,2 k.ring@qmul.ac.uk, Smuk, Melanie², Shongwe, Moses¹, Okonta, Leroy¹, Mackie, Nicola E.³, Ayres, Sara³, Barber, Tristan J.^4,5, Akodu, Jane⁴, Ferro, Filippo⁴, Chilton, Daniella⁶, Hurn, Eliot⁶, Halai, Bhavna⁶, Barchi, Will⁶, Ali, Asim⁶, Darko, Sandra⁶, White, Gemma⁶, Clarke, Emily⁷, Clark, Fiona⁸, Ali, Bazga⁸, Arumainayagam, Joseph⁹

المصدر: HIV Medicine. Oct2024, Vol. 25 Issue 10, p1125-1134. 10p.

مصطلحات موضوعية: *HIV integrase inhibitors, *RILPIVIRINE, *MEDICAL protocols, *VIROLOGY, *TERMINATION of treatment, *TREATMENT duration, *DESCRIPTIVE statistics, *INJECTIONS, *LONGITUDINAL method, *VIREMIA, *DRUG efficacy, *RESEARCH, *ACQUISITION of data, *PATIENTS' attitudes

مصطلحات جغرافية: UNITED Kingdom

المؤلفون: ViiV Healthcare

المصدر: Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.

المؤلفون: GlaxoSmithKline, PPD DEVELOPMENT, LP

المصدر: A Phase IIIb, Multi-center, Non-randomized, Parallel-group, Open-label, Hybrid Type I Study Evaluating the Efficacy, Safety, Implementation Effectiveness, and Patient-reported Outcomes of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Followed by Participant-determined Optional Switch to Long-acting Intramuscular Cabotegravir Plus Rilpivirine Every Two Months for the Maintenance of Virologic Suppression in Antiretroviral Therapy Naive Adults Living With HIV-1

Other URLs: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

المؤلفون: National Institute on Drug Abuse (NIDA)

المساهمون: Curt Beckwith, Professor of Medicine

المصدر: Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community (Study #3; Aim 2 Injectable CAB/RPV Pilot)

المؤلفون: Janssen Pharmaceuticals, GlaxoSmithKline

المصدر: A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022 Feb 1;36(2):185-194. doi: 10.1097/QAD.0000000000003025.
Chounta V, Snedecor SJ, Wu S, Van de Velde N. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection. BMC Infect Dis. 2022 May 4;22(1):428. doi: 10.1186/s12879-022-07243-3.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masia M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4.

Other URLs: https://clinicalstudydatarequest.com/Posting.aspx?ID=20382

المصدر: An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies

المصدر: 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

المصدر: An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

المؤلفون: Janssen Research & Development, LLC

المصدر: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, Garcia Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Espanol CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D'Amico R, Smith KY, Vandermeulen K, Spreen WR. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020.
Chounta V, Snedecor SJ, Wu S, Van de Velde N. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection. BMC Infect Dis. 2022 May 4;22(1):428. doi: 10.1186/s12879-022-07243-3.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Espanol CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022 Feb 1;36(2):185-194. doi: 10.1097/QAD.0000000000003025.
Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, van Solingen-Ristea R, Wang Y, Hudson KJ, Shaefer MS, Margolis DA, Smith KY, Spreen WR. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31.

Other URLs: http://clinicalstudydatarequest.com

المؤلفون: ViiV Healthcare

المصدر: Cabotegravir-Rilpivirine Long Acting (CAB-RPV LA) Implementation Strategies Among High-Risk Populations

المصدر: Implementation of Out-of-HOspital Administration of the Long-Acting Combination Cabotegravir+Rilpivirine as an Optional Therapy in HIV-Infected Patients From Spain: Acceptability, Appropriateness, Feasibility and Satisfaction: The HOLA Study

المساهمون: Castagna Antonella, Professor

المصدر: Cohort Study of HIV-positive People, Treated with Long Acting Antiretroviral Therapy (SCohoLART)
Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Espanol CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, Garcia Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masia M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466.
Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.
Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.
Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, Polli JW, Dorey D, Wang Y, Wu S, Van Eygen V, Crauwels H, Ford SL, Baker M, Talarico CL, Clair MS, Jeffrey J, White CT, Vanveggel S, Vandermeulen K, Margolis DA, Aboud M, Spreen WR, van Lunzen J. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021 Jul 15;35(9):1333-1342. doi: 10.1097/QAD.0000000000002883.
Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S, Gouws-Williams E, Ghys PD; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. Lancet HIV. 2020 Nov;7(11):e772-e781. doi: 10.1016/S2352-3018(20)30252-6.
Schlosser M, Kartashev VV, Mikkola VH, Shemshura A, Saukhat S, Kolpakov D, Suladze A, Tverdokhlebova T, Hutt K, Heger E, Knops E, Bohm M, Di Cristanziano V, Kaiser R, Sonnerborg A, Zazzi M, Bobkova M, Sierra S. HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. Viruses. 2020 Apr 22;12(4):475. doi: 10.3390/v12040475.
Charpentier C, Storto A, Soulie C, Ferre VM, Wirden M, Joly V, Lambert-Niclot S, Palich R, Morand-Joubert L, Landman R, Lacombe K, Katlama C, Ghosn J, Marcelin AG, Calvez V, Descamps D. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients. J Antimicrob Chemother. 2021 Oct 11;76(11):2983-2987. doi: 10.1093/jac/dkab161. Erratum In: J Antimicrob Chemother. 2021 Oct 11;76(11):3070. doi: 10.1093/jac/dkab295.
Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard HF, Paredes R, Shafer RW, Richman DD. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019 Sep;27(3):111-121.
Lai A, Franzetti M, Bergna A, Saladini F, Bruzzone B, Di Giambenedetto S, Di Biagio A, Lo Caputo S, Santoro MM, Maggiolo F, Parisi SG, Rusconi S, Gianotti N, Balotta C. Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. Clin Microbiol Infect. 2021 Jul;27(7):1038.e1-1038.e6. doi: 10.1016/j.cmi.2020.09.028. Epub 2020 Sep 23.
Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021 Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220. Epub 2020 Nov 6.

المؤلفون: Janssen Research & Development, LLC

المصدر: Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1

Other URLs: https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

المؤلفون: Bettonte, Sara^1,2 sara.bettonte@unibas.ch, Berton, Mattia^1,2, Stader, Felix³, Battegay, Manuel^1,2, Marzolini, Catia^1,2,4,5 sara.bettonte@unibas.ch

المصدر: Clinical Infectious Diseases. 8/15/2024, Vol. 79 Issue 2, p477-486. 10p.

مصطلحات موضوعية: *OBESITY complications, *RILPIVIRINE, *COMPUTER simulation, *ANTIRETROVIRAL agents, *RESEARCH funding, *BODY mass index, *INTRAMUSCULAR injections, *HIV infections, *DRUG monitoring, *DRUG efficacy, *PATIENT monitoring, *PHARMACODYNAMICS, *EVALUATION

مصطلحات جغرافية: UNITED States

المؤلفون: John, M.^1,2,3 mina.john@health.wa.gov.au, Williams, L.¹, Nolan, G.¹, Bonnett, M.¹, Castley, A.^1,2, Nolan, D.¹

المصدر: HIV Medicine. Aug2024, Vol. 25 Issue 8, p935-945. 11p.

مصطلحات موضوعية: *RILPIVIRINE, *PATIENT compliance, *SUBSTANCE abuse, *ANTIRETROVIRAL agents, *DRUG side effects, *HUMAN services programs, *RESEARCH funding, *CLINICAL trials, *INTRAMUSCULAR injections, *AT-risk people, *HIV infections, *TREATMENT duration, *DESCRIPTIVE statistics, *INJECTIONS, *DRUG efficacy, *DRUGS, *HEALTH outcome assessment, *SOCIAL support, *PATIENT satisfaction, *HEALTH care teams

مصطلحات جغرافية: AUSTRALIA

المؤلفون: Welzen, Berend J van¹ B.J.vanWelzen@umcutrecht.nl, Lelyveld, Steven F L Van², Beest, Gerjanne Ter³, Gisolf, Jet H³, Geerlings, Suzanne E⁴, Prins, Jan M⁴, Twillert, Gitte Van⁵, Nieuwkoop, Cees Van⁶, Valk, Marc Van der^4,7, Burger, David⁸, Wensing, Annemarie M J^9,10 B.J.vanWelzen@umcutrecht.nl

المصدر: Clinical Infectious Diseases. 7/15/2024, Vol. 79 Issue 1, p189-195. 7p.

مصطلحات موضوعية: *RILPIVIRINE, *HIV integrase inhibitors, *VIROLOGY, *ANTIRETROVIRAL agents, *HIV, *NON-nucleoside reverse transcriptase inhibitors, *BODY mass index, *ORAL drug administration, *INJECTIONS, *DRUG monitoring, *PROTEASE inhibitors, *CISGENDER people, *VIREMIA, *POLYNEUROPATHIES, *TREATMENT failure, *GENERIC drug substitution, *TRANS women, *GENETIC mutation, *CONFIDENCE intervals, *GENOTYPES, *SEQUENCE analysis, *TIME, *B cell lymphoma

مصطلحات جغرافية: NETHERLANDS